Skip to Content

Otezla Approval History

FDA Approved: Yes (First approved March 21, 2014)
Brand name: Otezla
Generic name: apremilast
Dosage form: Tablets
Company: Celgene Corporation
Treatment for: Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease

Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s Disease.

Development History and FDA Approval Process for Otezla

DateArticle
Jul 19, 2019Approval FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
Sep 23, 2014Approval FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis
Mar 21, 2014Approval FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide